Key result
Nylidrin and isoproterenol afforded significant protection against shock deaths and maintained cardiac output in dogs subjected to hemorrhagic shock, whereas phenoxybenzamine did not increase survival.
Why the study?
Do beta-adrenergic receptor stimulants (nylidrin and isoproterenol) improve survival and hemodynamics in dogs subjected to hemorrhagic shock compared to phenoxybenzamine?
Population
Anesthetized dogs subjected to 3 hours of hypovolemia (hemorrhagic shock) followed by the return of shed blood
Comparison
Nylidrin or isoproterenol administered 1 hour… vs Phenoxybenzamine and control
Design
Preclinical
Authors
Loading...
May guide beta-agonist testing in shock models; leaves open translation to human resuscitation.
Do beta-adrenergic receptor stimulants (nylidrin and isoproterenol) improve survival and hemodynamics in dogs subjected to hemorrhagic shock compared to phenoxybenzamine?
Beta-adrenergic stimulants nylidrin and isoproterenol improve survival and maintain cardiac output in a canine model of hemorrhagic shock.
Grega et al. (1967) studied Hemorrhagic shock. Nylidrin and isoproterenol vs. Phenoxybenzamine and control was evaluated on Survival rates. Nylidrin and isoproterenol afforded significant protection against shock deaths and maintained cardiac output in dogs subjected to hemorrhagic shock, whereas phenoxybenzamine did not increase survival.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: